March 2012 Br J Cardiol 2012;19(Suppl 1):s1-s16 doi:10.5837/bjc.2012.s03
Adie Viljoen
The global epidemic of obesity and type 2 diabetes, largely due to overconsumption and sedentary lifestyle, is a major challenge facing clinicians. In the UK, as in the European Region, the prevalence of obesity is rapidly increasing, highlighting a growing health challenge.1 In England (2003 data), 65% of males and 55% of females aged 16 years or more are either overweight or obese.1 As a consequence, the prevalence of the metabolic syndrome, of which dyslipidaemia (elevated triglycerides and low plasma levels of high-density lipoprotein [HDL] cholesterol) and central obesity are key features,2 is increasing. Therapeutic lifestyle intervent
August 2011 Br J Cardiol 2011;18:158–9
BJCardio Staff
Heart hotspots campaign The North/South divide in coronary heart disease (CHD) mortality remains significant despite improvements in cardiovascular disease (CVD) care, according to the ‘Heart Hotspots’ campaign launched at this year’s conference. The North West region has the highest mortality (93.72 per 100,000) versus South Central, which showed the lowest mortality (65.59 people per 100,000), according to NHS Information Centre data highlighted by the campaign (figure 1).1 CHD mortality in Tameside and Glossop, near Manchester, is almost four times as high as for those living in Kensington and Chelsea, London (140.84 vs. 36.91 people
February 2011 Br J Cardiol 2011;18:s13-s5
Julian Halcox - Professor of Cardiology and Consultant Cardiologist
To address the question of increasing engagement with CR programmes in target areas, in 2009, I chaired a Steering Committee convened by Abbott Healthcare Products Ltd. (formerly Solvay Healthcare) called ‘Setting the Standard for Cardiac Rehabilitation’ (START). The Steering Committee advised that the existing Cardiac Networks in each region would be the best forum for disseminating information about changes in CR funding and standards of care in this field. Abbott Healthcare Products Ltd. kindly agreed to organise a series of meetings in the UK, held during 2009 and early 2010, with the aim of raising awareness of the importance of CR a
February 2011 Br J Cardiol 2011;18:s13-s5
John Buckley
WHO definition The World Health Organization (WHO) defined CR in 1993 in a timeless way that is inclusive and sensitive to the psychosocial, biomedical, professional expertise and service delivery mode and location elements required of a contemporary CR service. “The sum of activities required to influence favourably the underlying cause of the disease so that (people) may by their own efforts preserve, or resume when lost, as normal a place in the community… …it must be integrated within secondary prevention services of which it forms one facet”.3 BACR definition This article reflects on how this definition dovetails with the BACR St
February 2011 Br J Cardiol 2011;18:s13-s5
Dr E Jane Flint
In fact, fewer than half of networks have ever benefited from Patient Choice Revascularisation Pathway monies, which were originally intended to support CR also.2 The START meeting in Birmingham in December 2009 was an opportunity to celebrate the innovative approach undertaken by the West Midlands’ Regional NSF Implementation Group for Cardiac Rehabilitation and Secondary Prevention, describing local CR pathway service standards against which West Midlands’ CR programmes could be audited to inform commissioning. The subsequent proportional allocation of ‘Patient Choice’ rehabilitation funding across Birmingham and the Black Country w
February 2011 Br J Cardiol 2011;18:s8-s10
Judith Edwards
The service at Charing Cross was used as the model for EUROACTION, a randomised, controlled trial of a preventive cardiology programme, conducted in eight European countries, including the UK. This nurse-led multidisciplinary programme significantly improved the management of lifestyle and medical risk factors for cardiovascular disease prevention in coronary patients and patients at high multifactorial risk for developing heart disease.1 The principles of the EUROACTION programme were used to found The MyAction community programme, commissioned in 2008 by NHS Westminster as a model for preventive cardiology care for its residents. The Imperi
February 2011 Br J Cardiol 2011;18:s11-s2
John Buckley
What is beneficial exercise? A prime question needs to be considered before furthering this discussion: what is meant by beneficial exercise? The benefits of exercise impact on all aspects of health – physiological, psychological and social. A study by Fox (1999) found that short bouts of any activity, even low-intensity activity that may not bring about a significant physiological risk factor change, if it is performed regularly, will provide psychological benefits to self-esteem and self-efficacy, and reductions in anxiety and depression.2 Angina patients engaging in regular walking on a similar premise to that expressed by Fox show signi
February 2011 Br J Cardiol 2011;18:s13-s5
Amarjit Sethi, John Townend, Adrian Brady, Julian Halcox
North West London To try and identify local barriers and share good practice, we have been regularly reviewing our cardiac rehabilitation (CR) services in North West London. Through this process we hope to increase the average uptake in a step-wise fashion from 50–60% to the national target of 85%.1 Lack of appropriately funded services and low staffing levels are real problems across the sector, unfortunately. Nevertheless, some innovative approaches to CR are taking place. The uptake of CR services after primary percutaneous coronary intervention (PPCI) for myocardial infarction has increased from 26% to 84% at Imperial College Healthcare
February 2010 Br J Cardiol 2010;17:13-18
BJCardio editorial staff
ARBITER 6: niacin superior to ezetimibe for slowing atherosclerosis Use of extended-release niacin resulted in a significant benefit on atherosclerosis compared with ezetimibe in patients already taking statins in the ARBITER 6-HALTS trial. The trial, presented at the meeting by Dr Allen Taylor (Medstar Research Institute, Washington DC, US), compared two distinct lipid-modifying strategies in patients with known vascular disease already on statins who had LDL-cholesterol levels <100 mg/dL (2.56 mmol/L) and moderately low HDL-cholesterol levels (<50 mg/dL [1.28 mmol/L]). Among the 363 patients enrolled in the study, half were randomised
November 2008 Br J Cardiol 2008;15:284–8
BJCardio editorial team
JUPITER shows large cardiovascular risk reduction in primary prevention The eagerly awaited landmark JUPITER trial shows that the treatment of apparently healthy patients – who had low levels of low-density lipoprotein (LDL) cholesterol but elevated C-reactive-protein (CRP) levels – with rosuvastatin cuts their risk of cardiovascular disease morbidity and mortality by around 50%. The results were the first late-breaking trial data reported here at the AHA 2008 Scientific Sessions and were also published in the New England Journal of Medicine (N Engl J Med 2008; 359: 2195-207). JUPITER was designed as a four-year study but was stopped in
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits